Paul Freiman - NovaBay Pharmaceuticals Independent Chairman of the Board
| NBY Stock | USD 0.57 0.03 5.00% |
Chairman
Mr. Paul E. Freiman serves as Independent Director of Novabay Pharmaceuticals Incorporation. Mr.Freiman has served as a director of NovaBay since May 2002. He also served as a director of NovaCal Pharmaceuticals from May 2001 to May 2002. Since January 2009, Mr. Freiman was an independent pharmaceutical professional and consultant. Mr. Freimans prior experience includes serving as the president and chief executive officer of Neurobiological Technologies, Inc. and a member of its board of directors from April 1997 until December 2008. Mr. Freimans prior experience also includes serving as the former chairman and chief executive officer of Syntex Corporation from 1989 to 1994, which was sold to The Roche Group for 5.3 billion during his tenure. He is credited with much of the marketing success of Syntexs lead product, Naprosyn, and was responsible for moving the product to overthecounter status, marketed as Aleve. Mr. Freiman currently serves on the Board of Neurotrope, Inc. since 2013. Mr. Freiman served as chairman of Penwest Pharmaceutical Co. until 2010, served on the board of directors of Otsuka American Pharmaceuticals, Inc. and Otsuka America, Inc. and served on the board of directors of NeoPharm, Inc. until 2010 and Calypte Biomedical Corporation until September 2009 since 2019.
| Age | 84 |
| Tenure | 5 years |
| Professional Marks | Ph.D |
| Address | 2000 Powell Street, Emeryville, CA, United States, 94608 |
| Phone | 510 899 8800 |
| Web | https://novabay.com |
NovaBay Pharmaceuticals Management Efficiency
The company has Return on Asset of (0.3867) % which means that on every $100 spent on assets, it lost $0.3867. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (2.6383) %, meaning that it generated no profit with money invested by stockholders. NovaBay Pharmaceuticals' management efficiency ratios could be used to measure how well NovaBay Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.12 in 2024. Return On Capital Employed is likely to drop to -1.1 in 2024. At this time, NovaBay Pharmaceuticals' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 2 M in 2024, whereas Other Assets are likely to drop slightly above 461.6 K in 2024.Similar Executives
| Found 3 records | CHAIRMAN Age | ||
| Pankaj Mohan | Sonnet Biotherapeutics Holdings | 59 | |
| Stephen Glover | ZyVersa Therapeutics | 64 | |
| Robert Bitterman | Phio Pharmaceuticals Corp | 73 | |
Management Performance
| Return On Equity | -2.64 | ||||
| Return On Asset | -0.39 |
NovaBay Pharmaceuticals Leadership Team
Elected by the shareholders, the NovaBay Pharmaceuticals' board of directors comprises two types of representatives: NovaBay Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of NovaBay. The board's role is to monitor NovaBay Pharmaceuticals' management team and ensure that shareholders' interests are well served. NovaBay Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, NovaBay Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Xiaopei Wang, Director | ||
| Andrew Jones, Chief Financial Officer, Treasurer | ||
| Swan Sit, Independent Director | ||
| Mijia Wu, Director | ||
| Audrey MD, Chief Director | ||
| Paul Freiman, Independent Chairman of the Board | ||
| Jeffrey MD, Pres DERMAdoctor | ||
| Justin Esq, CEO and President | ||
| Yenyou Zheng, Independent Director | ||
| Justin Hall, President, Chief Executive Officer, Director | ||
| Tommy Law, Interim Controller | ||
| Wang Xu, Controller and Senior Manager | ||
| Xinzhou Li, Director |
NovaBay Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is NovaBay Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.64 | ||||
| Return On Asset | -0.39 | ||||
| Profit Margin | (0.77) % | ||||
| Operating Margin | (0.43) % | ||||
| Current Valuation | 3.43 M | ||||
| Shares Outstanding | 4.89 M | ||||
| Shares Owned By Insiders | 0.02 % | ||||
| Shares Owned By Institutions | 2.58 % | ||||
| Number Of Shares Shorted | 187.04 K | ||||
| Price To Earning | (5.43) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for NovaBay Stock Analysis
When running NovaBay Pharmaceuticals' price analysis, check to measure NovaBay Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NovaBay Pharmaceuticals is operating at the current time. Most of NovaBay Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NovaBay Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NovaBay Pharmaceuticals' price. Additionally, you may evaluate how the addition of NovaBay Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.